Shanghai and Hong Kong, PRC, Nov. 22, 2021 - BioNova Pharmaceuticals Limited (BioNova) together with its joint venture subsidiary BK Pharmaceuticals Limited, today announced that it has filed a New Drug Application (NDA) for belumosudil for the treatment of chronic graft-versus-host disease (cGVHD) to the China National Medical Products Administration (NMPA).